Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis
Journal of Cellular Physiology · 2023
DOI: 10.1002/jcp.31036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular Physiology, 2023. Verfasst von Aleena Anwar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Immunology, Osteoimmunology & Immunoporosis Lab (TIOIL), Department of Biotechnology, All India Institute of Medical Sciences (AIIMS), …. Hauptthemen laut MEDLINE: Bone Resorption, Bone Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 294 Literaturangaben. Gefördert von: Indian Council of Medical Research, Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Osteoclasts, the bone‐resorbing cells, are essential for the bone remodeling process and are involved in the pathophysiology of several bone‐related diseases. The extensive corpus of in vitro research and crucial mouse model studies in the 1990s demonstrated the key roles of monocyte/macrophage colony‐stimulating factor, receptor activator of nuclear factor kappa B ligand (RANKL) and integrin αvβ3 in osteoclast biology. Our knowledge of the molecular mechanisms by which these variables control osteoclast differentiation and function has significantly advanced in the first decade of this century. Recent developments have revealed a number of novel insights into the fundamental mechanisms governing the differentiation and functional activity of osteoclasts; however, these mechanisms have not yet been adequately documented. Thus, in the present review, we discuss various regulatory factors including local and hormonal factors, innate as well as adaptive immune cells, noncoding RNAs (ncRNAs), etc., in the molecular regulation of the intricate and tightly regulated process of osteoclastogenesis. ncRNAs have a critical role as epigenetic controllers of osteoclast physiologic activities, including differentiation and bone resorption. The primary ncRNAs, which include micro‐RNAs, circular RNAs, and long noncoding RNAs, form a complex network that affects gene transcription activities associated with osteoclast biological activity. Greater knowledge of the involvement of ncRNAs in osteoclast biological activities will contribute to the treatment and management of several skeletal diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis, etc. Moreover, we further outline potential therapies targeting these regulatory pathways of osteoclastogenesis in distinct bone pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Immunology, Osteoimmunology & Immunoporosis Lab (TIOIL), Department of Biotechnology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Department of Allied Health Sciences, Chitkara School of Health Sciences, Chitkara University, Chandigarh, Punjab, India.
- Department of Zoology, Nehru Gram Bharati University, Prayagraj, Uttar Pradesh, India.
ORCID-Profile: Rupesh K Srivastava
Förderung
- Indian Council of Medical Research
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Anwar, A., Sapra, L., Gupta, N., Ojha, R. P., Verma, B., & Srivastava, R. K. (2023). Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31036
Vancouver
Anwar A, Sapra L, Gupta N, Ojha RP, Verma B, Srivastava RK. Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis. Journal of Cellular Physiology. 2023. doi:10.1002/jcp.31036
BibTeX
@article{Anwar2023,
author = {Anwar, Aleena and Sapra, Leena and Gupta, Navita and Ojha, Rudra P and Verma, Bhupendra and Srivastava, Rupesh K},
title = {Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis},
journal = {Journal of Cellular Physiology},
year = {2023},
doi = {10.1002/jcp.31036}
}
EUVIMED